Full-Time

Head – Clinical Development

Confirmed live in the last 24 hours

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

51-200 employees

Develops treatments for neurodegenerative diseases

Biotechnology
Healthcare

Senior, Expert

Remote in USA

Must reside and work within the United States in a state where Amylyx currently does business.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • MD required
  • Background in translational science is a plus.
  • 2+ years of experience in leading clinical development programs in the pharmaceutical industry with a proven record of achievements.
  • Ability to think critically and demonstrate troubleshooting and problem-solving skills.
  • Demonstrated leadership and team building skills as well as the ability to perform effectively in a multi-disciplinary environment.
  • Ability to lead directly and by influence, including strong interpersonal, problem solving, conflict resolution and analytical skills in a matrix environment.
  • Excellent communication skills (oral and written) and organizational skills.
  • Ability to travel internationally and domestically
Responsibilities
  • Provide medical monitoring to assigned neurology clinical trials
  • Provide clinical development leadership for programs that integrate extensive knowledge in clinical science and neurology, and inputs from the global medical community
  • Work closely with Medical Directors, Pharmacology, Drug Discovery, external experts, and investigators to accumulate scientific and medical knowledge necessary to support clinical development plans with a focus on pharmacodynamic endpoints
  • Integrates scientific rationale, regulatory requirements, product development plan, and value to patients and shareholders to build a solid Clinical Development Plan (CDP)
  • Accountable for production of highest quality program related documents, including protocols, IBs, clinical study reports, briefing documents and drug labels
  • Develop and maintain relationships with program counterparts in Research, Regulatory Affairs, Clinical Operations, Statistics and Contract Research Organizations (CROs)
  • Act as the primary Clinical Development interface with internal stakeholders as well as external subject matter experts and alliance partners for the assigned programs
  • Contribute to specific Business Development activities and various organizational initiatives in Clinical Development
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed positive results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in patients with early dementia related to Alzheimer's. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes and enhance the quality of life for individuals suffering from neurodegenerative conditions.

Company Stage

IPO

Total Funding

$166.7M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

-43%

1 year growth

-45%

2 year growth

-18%
Simplify Jobs

Simplify's Take

What believers are saying

  • Positive CENTAUR trial results boost AMX0035's potential for ALS treatment.
  • Growing interest in combination therapies could enhance AMX0035's efficacy.
  • Advancements in biomarker research may aid Amylyx's Alzheimer's trials.

What critics are saying

  • Relyvrio's Phase III failure led to market withdrawal, impacting financial stability.
  • 70% workforce reduction may hinder future R&D efforts.
  • Ongoing securities class action lawsuit could damage investor confidence.

What makes Amylyx Pharmaceuticals unique

  • Amylyx focuses on neurodegenerative diseases like ALS and Alzheimer's, unlike many competitors.
  • AMX0035 shows promise in multiple conditions, including ALS and Wolfram syndrome.
  • Amylyx's rigorous clinical trials, like CENTAUR and PEGASUS, enhance its credibility.

Help us improve and share your feedback! Did you find this helpful?